Procurement misses around recalls, mis-labeled units, or unstable lead times can stall surgeries and strain bedside care. This practical, compliance-first checklist is built for hospital purchasing, supply chain, MMIS/ERP, value analysis, and RA/QA partners evaluating advanced wound dressing suppliers (e.g., silicone foam, alginate, gelling fiber, antimicrobial Ag, contact layers). Use it to standardize RFP/RFI scoring, onboarding, and annual requalification—without slipping into marketing fluff.
If you need clinical background on dressing categories while you evaluate vendors, see these neutral overviews: the comparison on silicone foam vs. hydrocolloid and indications in the article “Best Wound Healing” and the context piece comparing alginate vs. hydrocolloid on SLK Medical’s education pages: silicone foam vs. hydrocolloid comparison and alginate vs. hydrocolloid comparison.
How to use this wound dressing supplier evaluation checklist
Scope covers US FDA (recalls, UDI/GUDID) and EU MDR (Basic UDI-DI, EUDAMED), plus GS1 barcoding and service performance (fill rate/OTIF, backorder comms) and lead‑time buffers.
Evidence to request is specified for each item. Set pass/fail thresholds by criticality tier (Critical/Important/Standard).
Suggested scoring: 100 points total; minimum 80 to onboard; ≥90 for preferred. Adjust per your governance.
Regulatory & Vigilance Due Diligence
Here’s the deal: before you talk price, clear the safety runway.
[ ] Recalls screen — last 36 months: Acceptance = No unresolved Class I/II recalls without documented CAPA and closure. Evidence: Printouts from the FDA’s searchable database with recall numbers, classes, reasons, and status; supplier CAPA summary and closure dates. Source: the official FDA Medical Device Recalls database and weekly Enforcement Reports pages.
[ ] Adverse event signals (MAUDE): Acceptance = No persistent trend (e.g., hypersensitivity, sterility, adhesion injuries) without supplier analysis and mitigations. Evidence: MAUDE query exports by product code/manufacturer and supplier response explaining trends and actions. Portal: the FDA’s MAUDE search interface with device/manufacturer filters.
] Early alerts monitoring: Acceptance = Documented SOP to scan FDA safety communications/early alerts, with internal escalation paths. Evidence: SOP and a log of monthly checks. Context: FDA’s curated [Medical Device Recalls and Early Alerts.
UDI, Traceability & Data Parity (US + EU)
] AccessGUDID verification (US): Acceptance = 100% DI match across label, ERP/MMIS, and AccessGUDID for a sample of SKUs; labeler name/DUNS match; GMDN term active and appropriate. Evidence: label photos, ERP item master export, AccessGUDID record screenshots. Authoritative background: FDA’s overview of the [GUDID public database and data elements.
[ ] PI flags alignment (US): Acceptance = PI presence on labels (lot, serial, expiry, mfg date as applicable) is accurately reflected in GUDID indicator fields; internal receiving can capture those PI values. Evidence: label images; GUDID field review; receiving SOP.
[ ] EU MDR readiness (EU): Acceptance = Basic UDI-DI assigned; supplier has Actor registration (SRN) and a plan to register devices in EUDAMED according to the 2026 mandate for the first four modules (Actor, UDI/Devices, Notified Bodies & Certificates, Market Surveillance). Evidence: Basic UDI-DI list, EUDAMED readiness letter, and (if available) NB correspondence. See the European Commission’s note that the first four EUDAMED modules become mandatory from 28 May 2026 in its official announcement.
[ ] Parity pitfalls you should test: brand/version text mismatches across label/ERP/GUDID; inactive or superseded DI in use; GMDN status errors; date-format inconsistencies; missing PI indicator flags versus packaging.
Neutral micro‑example: UDI mapping table (SLK‑style documentation format)
Below is a generic illustration of how a UDI mapping table is structured in many manufacturer documentation packets. It shows how hospitals can confirm DI/PI elements across label, ERP/MMIS, and public databases. This is an illustrative format only.
Data element | On label (HRI) | In barcode (GS1 AI) | ERP/MMIS field | Public record |
|---|---|---|---|---|
Device Identifier (DI/GTIN) | 00812345678901 | (01)00812345678901 | Item master: DI/GTIN | AccessGUDID DI record |
Lot/Batch | LOT A4521 | (10)A4521 | Lot field (receiving) | Not in GUDID (PI not stored) |
Expiration date | 2028‑11‑30 | (17)281130 | Expiry date | Not in GUDID (PI not stored) |
Serial (if applicable) | SN 002145 | (21)002145 | Serial/trace field | Not in GUDID (PI not stored) |
Brand + Version/Model | “Silicone Foam, 10×10 cm v2” | — | Description/attributes | GUDID brand + version/model |
Example note: A supplier like SLK Medical may provide a similar UDI mapping sheet in its documentation pack to support AccessGUDID checks and ERP parity reviews. This kind of sheet helps your receiving team validate that what’s on the label, in your system, and in the public database all line up.
GS1 Barcodes, Packaging & Clinical Scannability
[ ] GS1 carrier and content: Acceptance = Secondary packs carry GS1 DataMatrix encoding (01) GTIN plus (17) expiry and (10) lot; add (21) serial where applicable. Human Readable Interpretation printed adjacent, matching encoded data. Evidence: packaging artwork/spec and label images. Technical basis: GS1’s symbol, AI, and HRI rules in the current GS1 General Specifications.
[ ] Barcode print quality (verification): Acceptance = Meets ISO/IEC 15415 (2D) and 15416 (1D) verification with your contract‑specified minimum grade (e.g., ≥C/1.5/10 equivalent). Evidence: recent verifier reports and re‑verification cadence (e.g., quarterly or after process change).
[ ] Clinical scan tests (hospital reality check): Acceptance = Internal read‑rate target of ≥99.5% across representative scanners in receiving and at point of use; document scanners, lighting, and sample size. Evidence: test logs. Note: This is a pragmatic internal threshold to drive reliability; it’s not a GS1‑mandated number.
SLAs & Performance Monitoring
[ ] Fill rate (line/item) and OTIF: Acceptance = Set targets by criticality. As a starting point for critical SKUs, aim for line/item fill rate of 97–99% over a rolling 90 days and OTIF ≥98%. Evidence: monthly scorecards with clear calculation rules (denominators, exclusions). Context: AHRMM’s Keys outline internal fill‑rate expectations for hospitals; calibrate external supplier targets accordingly, referencing the AHRMM Keys 2025 overview.
[ ] Order accuracy and ASN timeliness: Acceptance = ≥99.8% order‑line accuracy; ≥99% ASNs transmitted within 24 hours of shipment. Evidence: EDI/portal logs.
] Backorder notification SLA: Acceptance = Supplier notifies within 24 hours of risk identification; during events, provides ETA windows and weekly (or more frequent) updates; escalation contacts named. Evidence: communication SOP and sample notices. Regulatory context: the FDA explains when and how manufacturers should notify the agency about potential supply disruptions under Section 506J; use that as a governance backstop in your contracts, per FDA’s page on [device supply notifications.
[ ] Substitutions and governance: Acceptance = Clear substitution rules for formulary‑approved alternates; medical review pathway documented. Evidence: SLA addendum and governance SOP.
Tip: Think of your SLA as the “operating system” for the relationship—definitions, thresholds, credits/penalties, and a no‑drama escalation tree.
Supply Continuity & Lead‑Time Buffers
[ ] Lead‑time stability: Acceptance = Supplier discloses quoted lead times and historical variability; you define acceptable variance bands and a quarterly review cadence. Evidence: historic lead‑time reports and S&OP summaries.
[ ] Safety stock (vendor DC and hospital): Acceptance = Commit to vendor DC safety stock on named SKUs (contracted levels) and set hospital policy targets—e.g., 8–12 weeks for critical items, tuned to demand and variability. Evidence: stocking agreements and inventory policy documents.
[ ] Dual sourcing and network resilience: Acceptance = When feasible, multi‑site production or dual‑source arrangements are identified for critical SKUs; risk register maintained. Evidence: supplier network map and risk register.
[ ] Disruption playbook: Acceptance = Named contacts, communication cadence, and recovery steps documented; triggers tied to stockout risk thresholds (e.g., <10 days on hand for critical SKUs).
Documentation Pack & Audit Evidence
[ ] QMS and registrations: Acceptance = Current ISO 13485 certificate (scope‑appropriate); US FDA establishment/device listings; EU MDR CE certificate/DoC where applicable. Evidence: certificates and registry references.
[ ] UDI policy and mapping: Acceptance = Written UDI assignment policy naming the issuing agency (GS1/HIBCC) and a UDI mapping table linking label DI/PI elements to ERP/MMIS fields and receiving workflows. Evidence: policy document; mapping table; AccessGUDID DI screenshots; for EU, EUDAMED readiness statement.
[ ] Barcode quality dossier: Acceptance = Recent ISO/IEC 15415/15416 verifier reports for representative SKUs and package levels; print process controls; re‑verification cadence. Evidence: verifier PDFs and SOPs.
[ ] Vigilance records: Acceptance = Recall logs and Field Safety Notices (last 36 months) with CAPA closures; change notification SOP and sample notices. Evidence: logs and SOPs.
[ ] SLA and performance pack: Acceptance = SLA with KPI definitions (fill rate, OTIF, accuracy, ASN timeliness), calculation methods (e.g., rolling 90 days), reporting cadence, service credits, and escalation language. Evidence: signed SLA and sample monthly scorecard.
Putting the checklist into motion
Embed parity checks into receiving: scan cartons, compare DI/brand/version to ERP and AccessGUDID on a defined sampling plan.
Require verifier reports at contract signature, then quarterly or with process changes.
Run a monthly supplier scorecard. Red/yellow/green thresholds trigger an escalation meeting.
Review lead‑time variance quarterly; update safety‑stock targets when demand shifts.
If you’d like a neutral sample pack (UDI mapping template, barcode verification sample, and SLA template) to adapt for your hospital, you can request a documentation set from SLK Medical. It’s a practical bundle meant to help you operationalize this checklist without reinventing the wheel.
References (authoritative starting points)
FDA Recalls database and early alerts: see the FDA Medical Device Recalls database and the curated page for Medical Device Recalls and Early Alerts for current safety signals.
AccessGUDID and data elements: FDA’s overview of the Global Unique Device Identification Database (GUDID) explains public DI records and core data rules.
EU EUDAMED modules: The European Commission states that four EUDAMED modules become mandatory from 28 May 2026 in its official announcement.
GS1 barcoding rules: Current AI, HRI, and symbol specs are in the GS1 General Specifications.
Hospital KPI context: Use the AHRMM Keys 2025 overview to calibrate internal fill‑rate expectations; align supplier SLAs accordingly.
Backorder governance: FDA’s page on device supply notifications under Section 506J clarifies manufacturer responsibilities during potential disruptions.
